The unique needs of patients with AML undergoing maintenance therapy, including care disparities and challenges, are discussed at the 2023 ONA Summit.
Researchers sought to determine whether OS rates with CAR-T therapy were linked to household poverty and neighborhood opportunity for patients with ALL.
Living along the Texas-Mexico border is associated with worse survival in children diagnosed with acute lymphoblastic leukemia.
Reinfusion with the CAR T-cell therapy tisagenlecleucel does not produce durable remissions in children and AYAs with B-ALL, a study suggests.
AML research presented at ASH 2022 highlighted promising combination regimens and suggested that some patients may benefit from less intensive treatment.